Eurocor Interventional Cardiology

Dedicated to Your heart.
Genius TAXCOR I
Clinically Advanced Drug-Eluting Technology to prevent restenosis, for the professional satisfaction of the cardiologist and for the benefit of the patient. Without polymer-induced, late adverse effect potential! Powered by BIOLOGY AND NATURE.

Genius TAXCOR I Coronary Stent System

"Stent Thrombosis is a growing concern"

Clinical Studies show 60% of stent thrombosis lead to a myocardial infarction*
45% of stent thrombosis lead to death.*


  • TAXCOR I reduces the risk of any polymer-induced, late adverse effect potential
  • TAXCOR I reduces the risk of subacute thrombosis by blood clot formation
  • TAXCOR I fully elutes the entire drug dosage in 26 days
  • TAXCOR I shows complete re-endothelialisation
  • TAXCOR I does require a dual antiplatelet therapy, which is limited to 6 months, after stent implantation
  • TAXCOR I provides a functionalized, bio-active, modified stent surface matrix, for the ideal attachment of the drug Paclitaxel

The Stent Platform: Bioflexibility reduces stenting trauma!

Genius MEGAflex is an ideal stent platform of TAXCOR I. MEGAflex provides biological-based coronary stent biomechanics to the arterial wall.
The bioflexible stent flexes in full conformity with the stented and flexing coronary artery, with every hearbeat. TAXCOR I minimizes the stent-induced arterial wall stress, thus the mechanical stenting trauma, which results in significantly lower neointimal hyperplasia reaction.

TAXCOR I provides superb deliverability and conformability, to the fullest satisfaction of the cardiologist.

Meet the next generation of coronary technology

Get the Flash Player and enable JavaScript to see this player.

A clinically, very effective drug

Paclitaxel is a clinically proven anti-restenosis agent. It prevents restenosis through the depolymerization and stabilization of micro-tubular-dependent activities like the prevention of smooth muscle cell division and migration.

It is also important, that Paclitaxel selectively inhibits proliferating smooth muscle cells. The endothelium cells present a better resistance to Paclitaxel, than the smooth muscle cells, due to the different affinity of the connective structure on the cell surface.

The TAXCOR I Paclitaxel-eluting coronary stent system balances neo-intimal growth and enhances a smooth re-endothelialization process.